Evidence map›Paper›PMID 34228136›Full record

ArticlePsychopharmacology2021

The GABA

Colin N Haile, Benjamin A Carper, Tracy L Nolen, Therese A Kosten

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Novel medications for problematic alcohol use.The Journal of clinical investigation · 2024
    Review
  4. Delving into the reducing effects of the GABAAlcohol (Fayetteville, N.Y.) · 2023
    Article
  5. Activation of GABANeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  6. Review
  7. Article
  8. The Novel Positive Allosteric Modulator of the GABAFrontiers in cell and developmental biology · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Colin N HaileDepartment of Psychology & TIMES, University of Houston, 4849 Calhoun Rd, Houston, TX, 77204-6022, USA. cnhaile@uh.edu.
Benjamin A CarperBiostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA.
Tracy L NolenBiostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA.
Therese A KostenDepartment of Psychology & TIMES, University of Houston, 4849 Calhoun Rd, Houston, TX, 77204-6022, USA.
RTI International · USUniversity of Houston · US

Funding

Office of the Secretary of Defense 3-312-0215031-52745L
6 · The paper itself

Abstract

rationalePre-clinical evidence implicates the GABAergic system in mediating the reinforcing effects of alcohol and offers a therapeutic target for alcohol use disorder (AUD). The orthosteric GABA

objectivesWe assessed the impact of the novel GABA

methodsThe effects of ASP8062 (1 - 10 mg/kg, PO) and baclofen (0.3 - 3 mg/kg, IP) were evaluated in male and female rats lever pressing for alcohol (10%, w/v) under a fixed ratio 2 schedule of reinforcement. On the fourth consecutive day of vehicle, ASP8062 or baclofen administration, active and inactive lever presses, reinforcers earned, head entries, and estimated alcohol consumed were analyzed. Locomotor activity was assessed in separate groups of rats following dosing.

resultsBoth ASP8062 and baclofen decreased alcohol self-administration and amount consumed (g/kg) in male and female rats. ASP8062 decreased operant alcohol self-administration to a greater extent in male rats, whereas baclofen was more efficacious in female rats. ASP8062 did not alter locomotor activity in either sex, whereas baclofen (3.0 mg/kg) decreased activity in male rats yet (1.0 mg/kg) increased activity in female rats.

conclusionsASP8062 decreases alcohol reinforcement like baclofen but without non-specific effects which are influenced by sex. Results support further development of ASP8062 as a potential treatment for AUD in humans.

Indexed as

PyrimidinesReceptors, GABA-BAllosteric RegulationAnimalsBaclofenConditioning, OperantFemaleGABA-B Receptor AgonistsMaleMorpholinesRatsRats, Sprague-DawleySelf AdministrationASP8062BaclofenGABA-B Receptor AgonistsMorpholinesPyrimidinesReceptors, GABA-BAlcohol use DisorderEthanolOperant respondingOral alcoholRepeated administrationSex differences

Identifiers

PMID34228136
OpenAlexW3180298022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.